低剂量贝林妥欧单抗治疗多重耐药类风湿关节炎的病例系列
该病例系列评估了低剂量贝林妥欧单抗在15例多重耐药类风湿关节炎(MDR-RA)患者中的安全性和有效性,中位年龄55岁。12周时9/15达到CDAI低疾病活动度、3/15达到CDAI缓解,滑膜B细胞清除而淋巴结未清除,部分患者对既往无效药物恢复应答,但14/15出现复发。
要点
- 低剂量贝林妥欧单抗在MDR-RA中短期控制疾病活动,12周时9/15达CDAI低疾病活动度。
- 安全性方面,3/15发生1级细胞因子释放综合征,无ICANS,1例低丙种球蛋白血症。
- 滑膜B细胞清除但淋巴结未清除,FAPI PET/CT显示关节摄取减少。
核心结论
- 低剂量贝林妥欧单抗可在3个月时短期控制MDR-RA疾病活动、清除滑膜B细胞并减少FAPI-PET成纤维细胞活化。
- 部分患者复发后对既往无效的改善病情抗风湿药恢复应答,低剂量TCE可能为MDR-RA提供可及的控制路径,但因果推断和普适性需对照试验验证。
研究设计与样本
- 研究为命名患者使用病例系列,纳入15例多重耐药类风湿关节炎患者,中位年龄55岁。
- 监测安全性(CRS、ICANS)、临床评分、超声和FAPI-PET/CT组织炎症,并在血液、滑膜和淋巴结中量化B细胞清除。
主要发现
- 15例中3例发生1级CRS,无ICANS发生,1例出现低丙种球蛋白血症。
- 1例在1年后发生致命心血管事件,治疗研究者判定为无关,但未经独立审查。
- 第12周疾病活动度下降,9/15达到CDAI低疾病活动度,3/15达到CDAI缓解。
- 滑膜B细胞清除(5例活检中4例),但淋巴结未清除;FAPI PET/CT显示受累关节示踪剂摄取减少。
- 14/15患者复发,但疾病活动度仍较低,7/15对既往失败的JAK抑制剂、阿巴西普或TNF抑制剂出现持续>3个月的应答。
关键数值与推荐
- 基线中位28关节疾病活动度评分C反应蛋白为5.0,临床疾病活动指数(CDAI)为28。
- 第12周9/15达到CDAI低疾病活动度,3/15达到CDAI缓解。
- 5例滑膜活检中4例显示滑膜B细胞清除,淋巴结未清除。
- 14/15患者复发,7/15对既往失败药物出现>3个月应答。
临床怎么用
- 低剂量贝林妥欧单抗可能作为多重耐药类风湿关节炎的短期疾病控制选择,需监测CRS和低丙种球蛋白血症。
- 治疗后复发常见,但部分患者对既往无效的改善病情抗风湿药恢复应答,可考虑再挑战。
局限性
- 研究为开放标签病例系列,样本量小(15例),无对照组,因果推断受限。
- 致命心血管事件未经独立审查,安全性评估可能不完整。
- 普适性需在对照试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: T-cell engagers (TCEs) are well-established treatments in haematology; strategies in autoimmune diseases are evolving. As an alternative to high-dose protocols optimising depletion, lower-dose protocols might optimise safety. METHODS: We assessed safety and efficacy of low-dose blinatumomab in a named patient use case series of 15 patients (median age 55) with multidrug-resistant rheumatoid arthritis (MDR-RA) (28-joint disease activity score C-reactive protein 5.0; clinical disease activity index [CDAI] 28). We monitored safety (cytokine release syndrome [CRS]; immune effector cell-related neurotoxicity syndrome [ICANS]), clinical scores, and tissue inflammation via ultrasound and fibroblast activation protein inhibitor (FAPI)-positron emission tomography/computed tomography (PET/CT). B-cell depletion was quantified in blood, synovium, and lymph nodes. RESULTS: CRS (grade 1) occurred in 3 of 15 patients. No ICANS occurred. One patient developed hypogammaglobulinaemia. One fatal cardiovascular event occurred after 1 year; it was adjudicated as unrelated by treating investigators but not independently reviewed. By week 12, disease activity decreased; 9 of 15 patients achieved CDAI low disease activity, and 3 of 15 patients achieved CDAI remission. Synovial B cells were depleted (4 of 5 biopsies) but not in lymph nodes. FAPI PET/CT showed reduced tracer uptake in the involved joints after blinatumomab. Although 14 of 15 patients flared, disease activity remained lower, and responsiveness lasting >3 months to previously failed drugs (Janus kinase inhibitors, abatacept, tumour necrosis factor inhibitors) was observed in 7 of 15 patients. CONCLUSIONS: Short-term control of RA disease activity, depleted synovial B cells, and reduced fibroblast activation on FAPI-PET were observed 3 months after blinatumomab. Flares after blinatumomab responded to previously ineffective disease-modifying antirheumatic drugs in some patients. Low-dose TCE therapy may offer an accessible path to disease control in MDR-RA, although causal inference and generalisability require validation in controlled trials.
引用
- Bucci L, Hagen M, Böltz S, et al. Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis-a case series. Ann Rheum Dis. 2026. PMID: 42595657. doi:10.1016/j.ard.2026.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。